Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers

May 13 2013

• By Derrick Gingery

Related Content

Pfizer Posts Weak First Quarter As It Continues To Mull Over A Split

Apr 30 2013

Breakthrough Therapies: FDA Not Writing A Scientific Guidance – Yet

Apr 29 2013

Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate

Feb 04 2013

First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?

May 06 2013

FDA’s First Breakthrough Designations Continue Vertex <em>Kalydeco</em>’s Regulatory Successes

Jan 07 2013

<em>Xalkori</em> And The Art Of Modern Drug Development

Feb 24 2012

Industry Wants A Breakthrough Therapy, Even Without All The Standards

Oct 29 2012

FDA To Provide Expedited Approval Desktop Reference

Oct 29 2012

Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year

Jan 31 2012

Related Companies

Merck & Co., Inc.

AbbVie Inc.

Bristol Myers Squibb Company

Pfizer Inc.

Vertex Pharmaceuticals Incorporated

Gilead Sciences, Inc.

Additional Topics

United States Drug Approval Standards BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window